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P. GINGUALIS ANTIGENC COMPOSITION

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional of U.S. patent application Ser. No. 1 1/729,218, filed Mar. 27.2007 , which is a continu ation of U.S. patent application Ser. No. 10/174,695, filed Jun. 18, 2002 , which is a continuation of PCT application number PCT/AU001/01588, filed Dec. 21, 2000, which claims priority to Australian application number PQ 4859, filed Dec. 24, 1999 , the contents of which are incorporated by reference in their entirety.
FIELD OF THE INVENTION
This invention provides an oral composition and an anti genic composition for use in the Suppression of the patho genic effects of the intra-oral bacterium Porphfromonas gin givalis associated with periodontal disease based on recombinant protein and antibodies. It also provides diagnos tic tests for the presence of Pgingivalis in subgingival plaque samples and specific anti-P gingivalis antibodies in Sera. Related thereto and disclosed is a method for preparing r-RgpA44 and r-Kgp39 and derivatives thereofusing recom binant DNA techniques. Also disclosed are host cells trans formed with recombinant vectors capable of expressing the recombinant proteins. The recombinant proteins are useful as immunogens in a vaccine formulation for active immuniza tion and can be used to generate protein-specific antisera useful for passive immunization and as reagents for diagnos tic assays.
BACKGROUND OF THE INVENTION
This invention relates generally to recombinant proteins of Porphfromonas gingivalis, r-Rgp A44 and r-Kgp39. The invention also relates to pharmaceutical compositions and associated agents based on these recombinant proteins and derivatives for the detection, prevention and treatment of periodontal disease associated with P gingivalis.
Periodontal diseases are bacterial-associated inflammatory diseases of the Supporting tissues of the teeth and range from the relatively mild form of gingivitis, the non-specific, revers ible inflammation of gingival tissue to the more aggressive forms of periodontitis which are characterised by the destruc tion of the tooth's Supporting structures. Periodontitis is asso ciated with a subgingival infection of a consortium of specific Gram-negative bacteria that leads to the destruction of the periodontium and is a major public health problem. One bacterium that has attracted considerable interest is P gingi valis as the recovery of this microorganism from adult peri odontitis lesions can be up to 50% of the subgingival anaero bically cultivable flora, whereas P gingivalis is rarely recovered, and then in low numbers, from healthy sites. A proportional increase in the level of P gingivalis in Subgin gival plaque has been associated with an increased severity of periodontitis and eradication of the microorganism from the cultivable Subgingival microbial population is accompanied by resolution of the disease. The progression of periodontitis lesions in non-human primates has been demonstrated with the Subgingival implantation of P gingivalis. These findings in both animals and humans Suggest a major role for P gin givalis in the development of adult periodontitis.
More recently there has been increasing linkage of pri odontal disease and cardiovascular disease and therefore a link between P gingivalis infection and cardiovascular dis 2 ease. More information regarding this linkage can be found in Beck, J D et al. Ann Periodontol. 3: 127-141, 1998 and Beck, J. et al. J. Periodontol. 67: 1123 -37, 1996 Pgingivalis expresses a range of proteins on its cell Surface that are potential candidates for the development of a vaccine or diagnostic. A major group of cell Surface proteins expressed by Pgingivalis is a group of proteinases and asso ciated adhesins. One proteinase designated Arg-gingipain has been disclosed previously by Travis et al. (PCT Publication No. WO95/07286). These investigators also reported a high molecular mass form of Arg-gingipain that is encoded by the genergp also disclosed in WO95/07286. The high molecular mass form of Arg-gingipain consists of the proteinase and several other proteins proposed to be adhesins. Cell-surface complexes of Pgingivalis consisting of Arg-and Lys-specific proteinases and adhesins have also been disclosed by Rey nolds et al. (PCT/AU96/00673). Neither of these disclosures provide teaching regarding the utility of a particular adhesin as a recombinant in the protection of P gingivalis infection.
SUMMARY OF THE INVENTION
In a first aspect the present invention consists in an anti genic composition, the composition comprising at least one recombinant protein, the recombinant protein comprising at least one epitope, the epitope being reactive with an antibody wherein the antibody is reactive with a polypeptidehaving the sequence set out in SEQ. ID. NO. 3 or SEQ. ID, NO. 5.
In a further preferred embodiment the antigenic composi tion comprises a recombinant protein having a sequence selected from the group consisting of SEQ. ID. NO. 3, resi dues 1-184 of SEQ. ID, NO. 3, residues 1-290 of SEQ. ID. NO.3, residues 65-184 of SEQ. ID, NO. 3, residues 65-290 of SEQ. ID. NO. 3, residues 65-419 of SEQ. ID. NO. 3, residues 192-290 of SEQ. ID, NO. 3, residues 192-419 of SEQ. ID. NO. 3, residues 147-419 of SEQ. ID, NO. 3, SEQ. ID. NO. 5 and SEQ. ID. NO. 6.
As will be noted from a comparison of SEQ. ID. NO. 3 and SEQ. ID. NO. 5 these polypeptides are identical over a sub stantial portion of their sequence.
In another preferred embodiment the antigenic composi tion further comprises an adjuvant.
In yet another preferred embodiment the recombinant pro tein is a chimeric or a fusion protein. Where the recombinant protein is a chimeric or a fusion protein it is preferred that protein include a sequence selected from the group consisting of SEQ. ID, NO. 3, residues 1-184 of SEQ. ID. NO. 3, resi dues 1-290 of SEQ. ID, NO. 3, residues 65-184 of SEQ. ID. NO.3, residues 65-290 of SEQ. ID, NO. 3, residues 65-419 of SEQ. ID. NO. 3, residues 192-290 of SEQ. ID. NO. 3, resi dues 192-419 of SEQ. ID, NO. 3, residues 147-419 of SEQ. ID, NO. 3, SEQ. ID. NO. 5 and SEQ. ID, NO. 6. An example of such a chimeric or a fusion protein is set out in SEQ. ID. NO. 4. In a second aspect the present invention consists in a com position, the composition comprising at least one antibody, the antibody being raised against the antigenic composition of the first aspect of the present invention.
In a third aspect the present invention consists in a recom binant prokaryotic or eucaryotic cell, the recombinant cell comprising a DNA sequence selected from the group consist ing of SEQ. ID. NO. 1, nucleotides 1-1257 of SEQ. ID. NO. 1, nucleotides 1-552 of SEQ. ID. NO.1, nucleotides 1-870 of SEQ. ID, NO. 1, As used herein, Stringent conditions are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% NaDodSO at 50° C.; (2) employ during hybridisation a dena turing agent Such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5 with 750 mMNaCl, 75 mM sodium citrate at 42°C.: or (3) employ 50% formamide, 5xSSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% Sodium pyrophosphate, 5xDenhardt's Solution, Sonicated salmon sperm DNA (50 g/ml), 0.1% SDS and 10% dextran Sulfate at 42°C. in 0.2XSSC and 0.1% SDS.
In a further aspect the present invention consists in a method of preventing or reducing the incidence or severity of P. gingivalis infection in a Subject, the method comprising administering to the Subject the antigenic composition of the first aspect of the present invention.
Given the increasing linkage of periodontal disease with cardiovascular disease (CVD) and the possible link therefore of Pgingivalis infection and CVD the antigenic composition of the first aspect of the present invention may also be used in a prophylactic therapy to reduce the incidence or severity of CVD or as an adjunct in treating CVD.
An important form of the invention is a vaccine based on the r-Rgp A44 and/or r-Kgp39 proteins or peptides and Suit able adjuvant delivered by nasal spray, orally or by injection to produce a specific immune response against the RgpA44 and/or r-Kgp39 protein. A vaccine can also be based upon a recombinant component of the RgpA44 and/or Kgp39 gene segment incorporated into an appropriate vector and expressed in a Suitable transformed host (e.g. E. coli, Bacillus subtilis, Saccharomyces cerevisiae, COS cells, CHO cells and HeLa cells) containing the vector. Component protein, peptides, and oligopeptides with immunogenic epitopes from the Rgp A44 and/or Kgp39 protein, can be used as immuno gens in various vaccine formulations in the prevention of periodontal diseases. Additionally, according to the present invention, the RgpA44 and/or Kgp39 proteins and related peptides or chimeras produced may be used to generate P gingivalis antisera useful for passive immunization against periodontal disease and infections caused by Pgingivalis.
According to one embodiment of the present invention, using recombinant DNA techniques the gene segment encod ing Rigp A44 and/or Kgp39, or gene fragments encoding one or more peptides or chimeras having immunogenic epitopes, is incorporated into an expression vector, and the recombi nant vector is introduced into an appropriate host cell thereby directing the expression of these sequences in that particular host cell. The expression system, comprising the recombinant vector introduced into the host cell, can be used (a) to produce r-RgpA44 and/or r-Kgp39 proteins, related peptides, oli gopeptides or chimeras which can be purified for use as an immunogen in vaccine formulations; (b) to produce Rigp A44 and/or Kgp39 protein, related peptides, oligopeptides and chimeras to be used as an antigen for diagnostic immunoas says or for generating Pgingivalis-specific antisera of thera peutic and/or diagnostic value; (c) or if the recombinant expression vector is a live virus such as vaccinia virus, the vector itself may be used as a live or inactivated vaccine preparation to be introduced into the hosts cells for expres sion of Rigp A44 and/or Kgp39 or immunogenic peptides or oligopeptides or chimeric peptides; (d) for introduction into live attenuated bacterial cells or genetically engineered com mensal intra-oral bacteria which are used to express RgpA44 and/or Kgp39 protein, related peptides or oligopeptides or chimeras to vaccinate individuals; (e) or for introduction directly into an individual to immunize against the encoded and expressed RgpA44 protein, related peptides, or oligopep tides or chimeras. In particular the recombinant bacterial vaccine can be based on a commensal inhabitant of the human oral cavity or animal if the vaccine is to prevent periodontal disease in animals. The recombinant bacterial vaccine expressing Pgingivalis Rigp A44 and/or Kgp39 can be used to colonise the oral cavity, Supragingival or subgingival plaque. The intra-oral bacterium can be isolated from the patient with periodontitis and genetically engineered to express the r-RgpA44 and/or r-Kgp39, components, peptides or chime ras. The r-Rgp A44 and/or r-Kgp39 protein will stimulate the mucosal-associated lymphoid tissues (NIALT) to produce specific antibody to P gingivalis. Rgp A44 and/or Kgp39 proteins, peptides, oligopeptides, chimeric peptides and constructs containing epitopes can be used as immunogens in prophylactic and/or therapeutic vac cine formulations against pathogenic strains of P gingivalis, whether the immunogen is chemically synthesized, purified from Pgingivalis, or purified from a recombinant expression vector system. Alternatively, the gene segment encoding RgpA44 and/or Kgp39, or one or more gene fragments encoding peptides or oligopeptides or chimeric peptides, may be incorporated into a bacterial or viral vaccine comprising recombinant bacteria or virus which is engineered to produce one or more specific immunogenic epitopes of Rgp A44 and/ or Kgp39, or in combination with immunogenic epitopes of other pathogenic microorganisms. In addition, the gene encoding Rigp A44 and/or Kgp39 or one or more gene frag ments encoding RgpA44 and/or Kgp39 peptides or oligopep tides or chimeric peptides, operatively linked to one or more regulatory elements, can be introduced directly into humans to express protein, peptide, oligopeptides or chimeric pep tides relating to the Rgp A44 and/or Kgp39 to elicit a protec tive immune response. A vaccine can also be based upon a recombinant component of normal or mutated Rgp A44 and/ or Kgp39 incorporated into an appropriate vector and expressed in a suitable transformed host (e.g. E. coli, Bacillus subtilis, Saccharomyces cerevisiae, COS cells, CHO cells and HeLa cells) containing the vector. The vaccine can be based on an intra-oral recombinant bacterial vaccine, where the recombinant bacterium expressing the P gingivalis RgpA44 and/or Kgp39 is a commensal inhabitant of the oral cavity.
In another aspect, the invention provides nucleotide sequences coding for the recombinant protein and functional equivalents of said nucleotide sequences and nucleic acid probes for said nucleotide sequences.
The invention also includes within its scope various appli cations and uses of the above nucleotides and recombinant products including chimeric recombinant polypeptides. In particular, the invention provides antibodies raised against the r-RgpA44 or r-Kgp39, herein called anti-r-Rgp A44 anti bodies and anti-r-Kgp39 antibodies, respectively; and anti bodies to the polypeptides, oligopeptides and chimeric pep tides. The antibodies may be polyclonal or monoclonal. The antibodies may be blended into oral compositions such as toothpaste, mouthwash, toothpowders and liquid dentifrices, mouthwashes, troches, chewing gums, dental pastes, gingival massage creams, gargle tablets, dairy products and other foodstuffs. The recombinant polypeptides, oligopeptides and chimeric peptides may also be used as immunogens in pro phylactic and/or therapeutic vaccine formulations. 5 In another aspect the invention provides a method of diag nosis for the presence of Pgingivalis characterised by the use of any one or a combination of an antibody, antigen or nucleic acid probe as hereinbefore defined comprising the application of known techniques including for example, enzyme linked immunosorbent assay.
The invention also provides diagnostic kits comprising antibodies, antigens and/or nucleic acid probes as hereinbe fore defined.
The invention also provides a method of treatment of a patient either Suffering from P gingivalis infection compris ing active vaccination of said patient with a vaccine as here inbefore defined and/or passive vaccination of said patient with an antibody as hereinbefore defined. Bound antibody was detected using a 1:4000 dilution of Goat anti-Rabbit HRP, and ELISA plates were read using a Lab systems iEMS microplate reader at 415 nm.
FIG. 5. Binding of recombinant Kgp39 protein to a variety of matrix proteins. The matrix proteins were coated at 5ug/ml and probed with recombinant protein which was then probed with anti-Rgp A-Kgp complex specific anti-sera: Collagen type V (-0-), Fibrinogen (--), Hemoglobin (-A-), and con trol (-X-). Bound antibody was detected using a 1:4000 dilu tion of Goat anti-Rabbit HRP conjugate, and ELISA plates were read using a Labsystems iEMS reader at 415 nm.
FIG. 6. Binding of recombinant Kgp39 protein fragment to a variety of matrix proteins. The matrix proteins were coated at 5 g/ml and probed with recombinant protein which was then probed with anti-Rgp A-Kgp complex specific anti-sera:
Collagen type V (-0-), Fibrinogen (--), Hemoglobin (-A-), and control (-X-). Bound antibody was detected using a 1:4000 dilution of Goat anti-Rabbit HRP conjugate, and ELISA plates were read using a Labsystems iEMS reader at 415 nm.
DETAILED DESCRIPTION
In order that the nature of the present invention may be more clearly understood preferred forms thereof will be described with reference to the following Examples.
The intra-oral bacterium Porphfromonas gingivalis con tains on its Surface a proteinase-adhesin complex encoded by the genes rgpA and kgp. The recombinant 44 kDa adhesin (r-RgpA44) of this proteinase-adhesin complex protects against P gingivalis challenge in a mouse abscess model whereas other recombinant proteins from the rgpA gene do not. The gene segment encoding the 44 kDa adhesin domain RgpA44 or Kgp39 can be cloned into an appropriate expres sion system to produce the recombinant protein, r-Rgp A44 or r-Kgp39. The purified r-RgpA44 or r-Kgp39 protein can then be used to generate antibodies using standard techniques. The animals used for antibody generation can be rabbits, goats, chickens, sheep, horses, cows etc. When a high antibody titre against the r-RgpA44 or r-Kgp39 protein is detected by immunoassay the animals are bled or eggs or milk are col lected and the serum prepared and/or antibody purified using standard techniques or monoclonal antibodies produced by fusing spleen cells with myeloma cells using standard tech niques. The antibody (immunoglobulin fraction) may be separated from the culture or ascites fluid, serum, milk or egg by salting out, gel filtration, ion exchange and/or affinity chromatography, and the like, with Salting out being pre ferred. In the salting out method the antiserum or the milk is saturated with ammonium Sulphate to produce a precipitate, followed by dialyzing the precipitate against physiological saline to obtain the purified immunoglobulin fraction with the specific anti-r-RgpA44 or anti-r-Kgp39. The preferred anti body is obtained from the equine antiserum and the bovine antiserum and milk. In this invention the antibody contained in the antiserum and milk obtained by immunising the animal with the r-Rgp A44 or r-Kgp39 protein or peptide is blended into the oral composition. In this case the antiserum and milk as well as the antibody separated and purified from the anti serum and milk may be used. Each of these materials may be used alone or in combination of two or more. Antibodies against the r-RgpA44 or r-Kgp39 can be used in oral compo sitions such as toothpaste and mouthwash. The anti-r-RgpA44 or anti-rkgp39 antibodies can also be used for the early detection of Pgingivalis in Subgingival plaque samples by a chairside Enzyme Linked Immunosorbent Assay (ELISA).
For oral compositions it is preferred that the amount of the above antibodies administered is 0.0001-50 g/kg/day and that the content of the above antibodies is 0.0002-10% by weight preferably 0.002-5% by weight of the composition. The oral composition of this invention which contains the above-men tioned serum or milk antibody maybe prepared and used in various forms applicable to the mouth such as dentifrice including toothpastes, toothpowders and liquid dentifrices, mouthwashes, troches, periodontal pocket irrigating devices, chewing gums, dental pastes, gingival massage creams, gargle tablets, dairy products and other foodstuffs. The oral composition according to this invention may further include additional well-known ingredients depending on the type and form of a particular oral composition.
In certain highly preferred forms of the invention the oral composition may be substantially liquid in character, Such as a mouthwash or rinse. In Such a preparation the vehicle is typically a water-alcohol mixture desirably including a humectant as described below. Generally, the weight ratio of water to alcohol is in the range of from about 1:1 to about 20:1. The total amount of water-alcohol mixture in this type of preparation is typically in the range of from about 70 to about 99.9% by weight of the preparation. The alcohol is typically ethanol or isopropanol. Ethanol is preferred.
The pH of such liquid and other preparations of the inven tion is generally in the range of from about 4.5 to about 9 and typically from about 5.5 to 8. The pH is preferably in the range of from about 6 to about 8.0, preferably The pH can be controlled with acid (e.g. citric acid or benzoic acid) or base (e.g. sodium hydroxide) or buffered (as with sodium citrate, benzoate, carbonate, or bicarbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, etc).
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Other desirable forms of this invention, the oral composi tion may be substantially solid or pasty in character, Such as toothpowder, a dental tabletor a dentifrice, that is a toothpaste (dental cream) or gel dentifrice. The vehicle of such solid or pasty oral preparations generally contains dentally acceptable polishing material. Examples of polishing materials are water-insoluble sodium metaphosphate, potassium meta phosphate, tricalcium phosphate, dihydrated calcium phos phate, anhydrous dicalcium phosphate, calcium pyrophos phate, magnesium orthophosphate, trimapesium phosphate, calcium carbonate, hydrated alumina, calcined alumina, alu minum silicate, Zirconium silicate, silica, bentonite, and mix tures thereof. Other suitable polishing material include the particulate thermosetting resins such as melamine-, phenolic, and urea-formaldehydes, and cross-linked polyepoxides and polyesters. Preferred polishing materials include crystalline silica having particle size of up to about 5 microns, a mean particle size of up to about 1. 1 n-Acrons, and a surface area of up to about 50,000 cm/gm, silica gel or colloidal silica, examples of Suitable materials. These metaphosphate salts exhibit only a minute solubility in water, and therefore are commonly referred to as insoluble metaphosphates (IMP). There is present therein a minor amount of soluble phosphate material as impurities, usually a few percent such as up to 4% by weight. The amount of soluble phosphate material, which is believed to include a soluble sodium trimetaphosphate in the case of insoluble metaphosphate, may be reduced or eliminated by washing with water if desired. The insoluble alkali metal metaphosphate is typically employed in powder form of a particle size such that no more than 1% of the material is larger than 37 microns. The polishing material is generally present in the solid or pasty compositions in weight concentrations of about 10% to about 99%. Preferably, it is present in amounts from about 10% to about 75% in toothpaste, and from about 70% to about 99% in toothpowder. In toothpastes, when the polishing material is silicious in nature, it is generally present in amount of about 10-30% by weight. Other polishing materials are typically present in amount of about 30-75% by weight.
In a toothpaste, the liquid vehicle may comprise water and humectant typically in an amount ranging from about 10% to about 80% by weight of the preparation. Glycerine, propy lene glycol, Sorbitol and polypropylene glycol exemplify Suitable humectants/carriers. Also advantageous are liquid mixtures of water, glycerine and Sorbitol. In clear gels where the refractive index is an important consideration, about 2.5-30% w/w of water, 0 to about 70% w/w of glycerine and about 20-80% w/w of sorbitol are preferably employed.
Toothpaste, creams and gels typically contain a natural or synthetic thickener or gelling agent in proportions of about 0.1 to about 10, preferably about 0.5 to about 5% w/w. A suitable thickener is synthetic hectorite, a synthetic colloidal magnesium alkali metal silicate complex clay available for example as Laponite (e.g. CP. SP 2002, D) marketed by Laporte Industries Limited. Laponite D is, approximately by weight 58.00% SiO, 25.40% MgO, 3.05% NaO, 0.98% LiO, and some water and trace metals. Its true specific grav ity is 2.53 and it has an apparent bulk density of 1.0 g/ml at 8% moisture.
Other Suitable thickeners include Irish moss, iota carrag eenan, gum tragacanth, starch, polyidnylpyrrolidone, hydroxyethylpropylcellulose, hydroxybutyl methyl cellu lose, hydroxypropyl methylcellulose, hydroxyethylcellulose (e.g. available as Natrosol), sodium carboxymethyl cellulose, and colloidal silica Such as finely ground Syloid (e.g. 244). Solubilizing agents may also be included Such as humectant polyols such propylene glycol, dipropylene glycol and hexy lene glycol, celloSolves such as methyl celloSolve and ethyl celloSolve, vegetable oils and waxes containing at least about 12 carbons in a straight chain such as olive oil, castor oil and petrolatum and esters such as amyl acetate, ethyl acetate and benzyl benzoate.
It will be understood that, as is conventional, the oral prepa rations are to be sold or otherwise distributed in suitable labeled packages. Thus, ajar of mouthrinse will have a label describing it, in Substance, as a mouthrinse or mouthwash and having directions for its use; and a toothpaste, cream or gel will usually be in a collapsible tube, typically aluminum, lined lead or plastic, or other squeeze, pump or pressurized dispenser for metering out the contents, having a label describing it, in Substance, as a toothpaste, gel or dental CCa:
Organic surface-active agents are used in the compositions of the present invention to achieve increased prophylactic action, assist in achieving thorough and complete dispersion of the active agent throughout the oral cavity, and render the instant compositions more cosmetically acceptable. The organic Surface-active material is preferably anionic, non ionic or ampholytic in nature which does not denature the antibody of the invention, and it is preferred to employ as the Surface-active agent a detersive material which imparts to the composition detersive and foaming properties while not denaturing the antibody. Suitable examples of anionic Surfac tants are water-soluble salts of higher fatty acid monoglycer ide monosulfates, such as the Sodium salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids, higher alkyl Sulfates such as Sodium lauryl Sulfate, alkyl aryl Sulfonates such as Sodium dodecylbenzene Sulfonate, higher alkylsulfo-acetates, higher fatty acid esters of 1,2-dihydroxy propane Sulfonate, and the Substantially saturated higher ali phatic acyl amides of lower aliphatic amino carboxylic acid compounds, such as those having 12 to 16 carbons in the fatty acid, alkyl or acyl radicals, and the like. Examples of the last mentioned amides are N-lauroyl sarcosine, and the Sodium, potassium, and ethanolamine salts of N-lauroyl, N-myristoyl, or N-palmitoyl sarcosine which should be substantially free from Soap or similar higher fatty acid material. The use of these sarconite compounds in the oral compositions of the present invention is particularly advantageous since these materials exhibit a prolonged marked effect in the inhibition of acid formation in the oral cavity due to carbohydrates breakdown in addition to exerting some reduction in the solu bility of tooth enamel in acid solutions. Examples of water soluble nonionic surfactants; suitable for use with antibodies are condensation products of ethylene oxide with various reactive hydrogen-containing compounds reactive therewith having long hydrophobic chains (e.g. aliphatic chains of about 12 to 20 carbon atoms), which condensation products ("ethoxamers') contain hydrophilic polyoxyethylene moi eties. Such as condensation products of poly (ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alco hols (e.g. Sorbitan monostearate) and polypropyleneoxide (e.g. Pluronic materials).
Surface active agent is typically present in amount of about 0.1-5% by weight. It is noteworthy, that the surface active agent may assist in the dissolving of the antibody of the invention and thereby diminish the amount of solubilizing humectant needed.
Various other materials may be incorporated in the oral preparations of this invention Such as whitening agents, pre 10 
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The following examples are further illustrative of the nature of the present invention, but it is understood that the invention is not limited thereto. All amounts and proportions referred to herein and in the appended claims are by weight unless otherwise indicated. EXAMPLE 1.
Cloning and expression of the P gingivalis proteinase and adhesin domains Rigp A45, Rgp A44, Rgp A27 and Rgp A15 in E. coli and testing of the recombinant proteins as a vaccine in the murine abscess model. Oligonucleotide primers used for the amplification of the nucleotide sequences encoding Rigpa45, RgpA44, RgpA27 and RCDA15.
Recombinant Protein Primers
RgpA45
Forward 5 ' -GCGCAGATCTTACACACCGGTAGAGG-3 ' ' (SEQ ID NO. : 9) Reverse 5" -GCGCGTCGACTTAGCGAAGAAGTTCGGGG-3 ' ' (SEQ ID NO. : 10)
RgpA44
Forward 5'-GCGCCATATGAGCGGTCAGGCCGAGATTGTTCTTG-3 ' ' (SEO ID NO. : 11) Reverse 5 ' -GCGCCTCGAGGCGCTTGCCATTGGCCTTGATCTC-3 ' ' (SEO ID NO. : 12)
RgpA27
Forward 5 ' -GCGCGCTAGCGTATACATGGCCAACGAAGCCAAGG-3 ' ' (SEQ ID NO. : 13) Reverse 5 ' -GCGCAGATCTCTTGATAGCGAGTTTCTC-3 ' ' (SEO ID NO. : 14)
RgpA15
Forward 5'-GCGCGCTAGCGTATACATGGCAGACTTCACGGAAACGTTC-3 ' ' (SEO ID NO. : 15) Reverse 5 ' -GCGCAGATCTTTTGGCGCCATCGGCTTCCG-3 ' ' (SEO ID NO. : 16) servatives, silicones, chlorophyll compounds and/or ammo niated material Such as urea, diammonium phosphate, and mixtures thereof. These adjuvants, where present, are incor porated in the preparations in amounts which do not Substan tially adversely affect the properties and characteristics desired.
Any suitable flavoring or Sweetening material may also be employed. Examples of Suitable flavoring constituents are flavoring oils, e.g. oil of spearmint, peppermint, wintergreen, Sassafras, clove, Sage, eucalyptus, marjoram, cinnamon, lemon, and orange, and methyl salicylate. Suitable Sweeten ing agents include Sucrose, lactose, maltose, Sorbitol. Xylitol, Sodium cyclamate, perillartine, AMP (aspartyl phenylala nine, methyl ester), saccharine, and the like. Suitably, flavor and Sweetening agents may each or together comprise from about 0.1% to 5% more of the preparation.
In the preferred practice of this invention an oral compo sition according to this invention Such as mouthwash orden tifrice containing the composition of the present invention is preferably applied regularly to the gums and teeth, Such as every day or every second or third day or preferably from 1 to 3 times daily, at a pH of about 4.5 to about 9, generally about 5.5 to about 8, preferably about 6 to 8, for at least 2 weeks up to 8 weeks or more up to a lifetime.
The compositions of this invention can be incorporated in lozenges, or in chewing gum or other products, e.g. by Stirring into a warm gum base or coating the outer Surface of a gum base, illustrative of which may be mentionedjelutong, rubber latex, vinylite resins, etc., desirably with conventional plasti cizers or softeners, Sugar or other Sweeteners or Such as glucose, Sorbitol and the like.
The composition of this invention also includes targeted delivery vehicles such as periodontal pocket irrigation devices, collagen, elastin, or synthetic sponges, membranes or fibres placed in the periodontal pocket or used as a barrier membrane or applied directly to the tooth root. Each of the proteinase and adhesin domains of the gene rgp A were amplified using the primers listed in Table 1 , P. gingivalis W50 genomic DNA with Elongase R (Gibco BRI) DNA polymerase and a PC-960 thermal cycler (Corbett Research Technologies). Using the oligonucleotide primers a PCR was performed essentially as described in the Elongase instruction protocol using the following conditions: 25 cycles of denaturation (94°C., 30 sec), annealing (50° C., 45 sec), and extension (70° C., 1.5 min). The PCR product was puri fied using PCR Spinclean R (Progen) and ligated into plasmid vector pGEMT-easy (Promega) and transformed into compe tent E. coli JM109 (Promega) following the manufacturers protocols. All procedures were similar for the preparation of the four recombinants so the detailed process for the RgpA44 only will be described. Recombinant plasmid pGEMT-easy RgpA44DNA was digested with NdeI and XhoI to release the insert DNA. Insert DNA was isolated by agarose gel electro phoresis (0.8%) and purified using the Qiafilter gel extraction kit (Qiagen). Purified insert DNA was ligated into Qiafilter purified plasmid expression vector pBT28a (Novagen) that had been previously digested with Ndel and XhoI, and the ligation products were transformed into the non-expression host, E. coli JM109. The recombinant pFT28-RgpA44 plas mid was then transformed into the E. coli expression host, HMS174(DE3) and selected on LB containing 50 ug kana mycin. The r-Rgp A44 expressed from pET28a contains a hexahistidine tag fused to the N-terminus of the expressed recombinant protein. r-Rgp A44 expression was induced by addition of IPTG and purified by nickel-affinity chromatog raphy. The integrity of the insert of plT28-RgpA44 was confirmed by DNA sequence analysis.
Expression of Recombinant E. Coli
A single colony transformant was used to inoculate 10 mls of Luria-Bertani broth containing 50 ug/mlkanamycin at 37° C. until the optical density (OD) was 1.0. This inoculum was then used to inoculate 500 ml of Terrific broth (contain ing potassium phosphates and 50 ug/ml kanamycin). The ODoo of this culture was allowed to reach 2.0 before induc ing with 0.1 mM IPTG. After a 4.5 hour induction period at 37°C. the culture was harvested by centrifuging at 4000 rpm for 20 min at 4°C. and the pellet was stored at -70° C. for the extraction of inclusion bodies.
Isolation and Solubilisation of Inclusion Bodies
The bacterial pellet was thawed on ice and resuspended in binding buffer (5 mM imidazole, 500 nM. NaCl, 20 mM Tris-HCl, pH 7.9), then sonicated and centrifuged at 20,000xg to collect the inclusion bodies. The pellet was resuspended in binding buffer and the process of Sonication and centrifugation repeated twice more to release further protein. The pellet was then resuspended in binding buffer containing 6 Murea and incubated on ice for 2-3 hrs stirring to completely dissolve proteins. Any remaining insoluble material was removed by centrifuging at 39,000xg for 20 min. The Supernatant was filtered through a 0.45 um mem brane before column purification. Nickel-Nitrilotriaectic Acid (Ni-NTA) Purification and Refolding of Solubilised Inclusions Ni-NTA metal affinity chromatography was used to purify the recombinant proteins via the He tag. Briefly, proteins were batch bound to the equilibrated Ni-NTA resin (Qiagen) which was poured into a small column and unbound proteins were eluted under gravity. The column was then washed with 10 volumes of binding buffer followed by 5 column volumes of wash buffer (60 mM imidazole, 500 mM. NaCl, 20 mM Tris HCl, 6Murea, pH 7.9). The bound protein was then eluted in buffer containing 1Mimidazole, 500 mMNaCl, 20 mM Tris HCl, 6Murea, pH 7.9).
Renaturation Of Recombinant Protein
Fractions eluted off the NI-NTA resin were pooled and refolded by the step-wise dialysis from 6 M to 3 M to 1.5 M to 0MUrea contained in the following buffer 0.5M Tris-HCl, 50 mM. NaCl and 8% Glycerol. Polyacrylamide Gel Electrophoresis and Western Blotting SDS-PAGE was performed as described by Laemmli. Samples were mixed with an equal Volume of 2x sample reducing buffer, boiled for 10 min at 95° C. and ran on Tris-glycine 12% gels (Novex). Molecular weight standards (SeeBlueTM) were also purchased from Novex. Western blots were prepared by electroblotting proteins onto nitrocellulose for 1 hr at 100 volts. Membranes were blocked with 1% casein solution before incubating with primary antibody diluted to 1/1000, washed and incubated with an goat anti-rabbit-BRP conjugate (KPL) washed and developed with TMB mem brane peroxidase substrate (KPL). Polyclonal antiserum was raised to the purified recombi nant proteins by dosing BALB/c mice with 2x20g of recom binant protein in Freunds incomplete adjuvant (Sigma) three weeks apart. Mice were bled one week after the second dose and the antiserum generated was used to screenWestern blots of whole cell P gingivalis W50 run under denaturing, reduc ing conditions.
The purity of the recombinant proteins was confirmed using MALDI-TOF mass spectrometry and N-terminal sequence analysis.
Murine Lesion Model
Groups of 10 female BALB/c mice (6-8 weeks old) were immunized (20 ug) Subcutaneously with each recombinant protein, r-RgpA45, r-Rgp A44, r-Rgp A27 and r-RgpA15 as well as formalin-killed P gingivalis cells and E. coli: all emulsified in Incomplete Freunds Adjuvant. The immuniza tions were given at the base of the tail and occurred four weeks and one week prior to challenge with Pgingivalis. Two days prior to challenge mice were bled from the retrobulbar plexus. BALB/c mice were challenged with 7.5x10 viable cells of P gingivalis 33277 subcutaneously in the abdomen. Following challenge, mice were examined daily for the num ber and size of lesions over a period of seven days. Lesions developed on the abdomen of the mice and the maximum lesion size in MM is presented in FIG.1. Significant reduc tions in lesion size were obtained only with vaccination using formalin-killed whole P gingivalis cells and the recombinant adhesin r-Rgp A44. The other recombinant proteins from the rgpA gene did not significantly reduce lesion size.
This example demonstrates the Superiority of r-RgpA44 over the other recombinant proteins from the rgpA gene in protection against P gingivalis challenge. EXAMPLE 2 In the previous example it was demonstrated that the recombinant 44 kDa adhesin protected against challenge with P. gingivalis in the mouse lesion model. However the full length 44 kDa adhesin when expressed in E. coli was found as inclusion bodies that were only soluble in denaturing Sol vents. A series of fragments from the 44 kDa adhesin were generated in order to improve the solublility of the protein and enhance the correct folding of the recombinant protein. The oligonucleotide primers used to construct fragments of the 44 kDa adhesin recombinant protein are shown in Table 2 . Using similar methods as described in Example 1, frag ments of the 44 kDa adhesin were cloned into pET24b plas mids (Novagen) and expressed in E. coli strain BL21 (DE3) (Novagen). Expression levels and the amount of soluble r-44 kDa protein produced were assessed for the different frag ments. This was done following IPTG induction, where by a 1.5 ml cell culture of the recombinant E. coli cell culture was pelleted by centrifugation and resuspended in 150 ul of bind ing buffer. Cells were then sonicated for 10 sec using a micro probe at a setting of 5 (Virosonic Digital 475 ultrasonic cell disruptor. The Virtis Company, NY). Following centrifuga tion for 3 minutes (10,000 rpm) the supernatant was collected, which represented the soluble fraction. The pellet was then washed and the resuspended in binding buffer, which repre sented the insoluble fraction. Analysis of the various fractions was carried out using Western blot analysis and SDS-PAGE. The results of these experiments are shown in Table 3 . The stability of ther-44 kDa protein or fragments thereof may also be further enhanced by the site directed mutagenisis of all or selected cysteine residues to serine or alanine residues.
The 44 kDa adhesin contains six Cys residues that form disulphides when oxidized which may result in incorrect folding and possibly lead to the formation of insoluble pro tein. The stability of the r-44 kDa protein or fragments of the r-44 kDa protein may therefore be further enhanced by the site directed mutagenisis of all or selected cysteine residues to serine or alanine residues. In addition to using fragments of the 44 kDa adhesin, chimeric proteins may be constructed using one or more fragments of the 44 kDa adhesin with other proteins or protein fragments from other P gingivalis proteins. Sequence ID 2 and 4 give one such example of a chimeric recombinant protein derived from a fragment of the 44 kDa adhesin (Frag ment 6 residues 192-290) linked to another P gingivalis pro tein fragment derived from PG33 (Genbank accession num ber AF 175715) a 95 residue C terminal fragment (residues 286-380). In total this chimeric protein has a total of 194 residues.
This chimeric recombinant fusion protein of fragments from the 44 kDa and PG33 proteins was produced by ampli fying the PG33 G-terminal fragment by PCR as described in Example I using the following primers. This PCR product was subcloned into the SalI and NotI sites of pET24b to generate pET24b::PG33C. The 44 kDa fragment 6 PCR product (see example 2 for primers) was then subcloned into the EcoRI and Sail of the pET24b::PG33C plasmid to generate a fusion construct of 44 kDa/PG33 i.e. pET24b::PG44f6-PG33C. When this plasmid was trans formed into E. coli strain BL21 (DE3) and expression studies performed as outlined in Examples 1 and 2, high levels of the chimeric 44 kDa/PG33 recombinant protein were obtained which was soluble when tested as in Example 2.
15 16 EXAMPLE 4 following conditions: 25 cycles of denaturation (94°C., 45 sec), annealing (52°C., 30 sec), and extension (72°C., 60
Mouse antisera raised to the recombinant 44 kDa or recom-sec). The PCR product was ligated into plasmid vector binant fragments of the 44 kDa protein react with paraform-pGEMT-easy (Promega) and transformed into competent E. aldehyde fixed whole P gingivalis cells indicating that 5 coli JM109 (Promega) as previously described. All proce immuno-reactive epitopes are conserved in the recombinant dures were identical for the preparation of both Kgp39 and proteins.
Kgp39 fragment recombinants and are essentially as Mouse antisera were obtained by immunising BALB/c described above for recombinant Rgp44 fragments. Recom mice with the recombinant full length 44 kDa protein or with binant plasmid pGEMT-easv-Kgro39 DNA digested with a recombinant fragment of the 44 kDa protein as described in 10 SE R A.d the nicd 'Ert DNy s tO Examples 1 and 2. P. gingivalis (strain W50) was anaerobi cally grown to log phase in brain heart infusion broth (Oxoid) purified plasmi d expression vector pET28b (Novagen) that
Supplemented with 5ug/ml heminand 1 lug/ml vitamin Kand had been previously digested with SalI and XhoI. Ligation products were transformed into the non-expression host, E. 0.5 mg/ml Cysteine. Cells were sedimented by centrifugation for 15 min at 10,000 rpm at 4°C. and resuspended in phos-15 coli JM109 and then transformed into the E. coli expression phate-buffered saline (PBS) containing 1% (wt/vol) host, HMS174(DE3) aS previously described. r-Kgp39 paraformaldehyde. Bacteria were placed at 4°C. overnight, expression was induced by addition of IPTG and purified by then washed and resuspended in PBS to an optical density of nickel-affinity chromatography. The integrity of the insert of 0.25 at OD600 (1x10 cells/ml). Killed bacteria were then pET28b-Kgp39 was confirmed by DNA sequence analysis. mixed in 10 ulaliquots with pooled mouse polyclonal sera at 20 Expression Of Recombinant E. Coli a dilution of 1:100 in 0.22um filtered PBS+10% FBS+0.01%
Recombinant Kgp39 and Kgp39 fragment proteins were Azide (PBS/FA) for 15 min at room temperature. The cells expressed by induction with IPTG using similar methodology were washed with PBS/FA and were subsequently incubated as that described for rRgp44 fragments. Briefly, single colony 15 min with 1 ul of FITC-labelled anti-mouse Immunoglo-transformants were used to inoculate 5 ml LB containing 50 bulin (Silenus) at a dilution of 1:100 in PBS/FA. The cells 25 Lig/ml kanamycin at 37° C. on an orbital shaker overnight.
were then washed and resuspended in 1 ml of PBS/FA. This culture was then used to inoculate 100 ml of fresh
The fluorescence intensity of stained Pgingivalis cells was medium and grown to mid-log growth phase (ODoo-0.6quantified using a FACS Calibur-activated fluorescence cell 1.0) before inducing with 0.5 mM IPTG for 6 hours. Cells sorter (Becton Dickinson) using the 488 nm wavelength band were then harvested by centrifugation at 6500xg and stored at generated from a 15 mW argon ion laser. Filtered PBS/FA 30 -20°C. overnight for the extraction of inclusion bodies. was used as the sheath fluid. FITC emission signals were Isolation and Solubilisation of Inclusion Bodies collected for each analysis which consisted of 20,000 gated
The bacterial pellet was thawed on ice and resuspended in events that were collected on the basis of size and granularity 10 mls of buffer B (20 mMNaHPO, 0.5M NaCl, 8Murea). using CELLOuest software (Becton Dickinson).
The redissolved cell pellet was sonicated on ice for 3x30 The results are shown in FIG. 3 . The % marked on each 35 second bursts at 30 second intervals using a Branson Soni panel indicates the percentage of P gingivalis cells staining fierR 250 Cell disruptor (Branson Ultrasonics Corporation, positively i.e., with a fluorescence intensity above the back-Danbury, Conn.) with the microtip on setting 3. Insoluble ground levels seen with no antisera or with Sera from normal cellular debris was removed by centrifugation at 39000xg for mice. All of the recombinant proteins produced antisera that 30 minutes at 4° C. and the Supernatant collected. The reacted with the majority of Pgingivalis cells although anti-40 insoluble cellular fraction was resuspended in 10 mls of sera to Fragment 4 showed a reduced reactivity compared to Buffer B. Sodium azide (0.001% v?v) was added to all the other r-44 kDa antisera. samples prior to storage at 4°C. Samples were then analysed by SDS-PAGE. Oligonucleotide primers used for the amplification of the nucleotide sequences encoding Kgb39 Kgp39 and Kgp39 fragment adhesin domains were ampli-(FPLC) instrument. The column was coated with 5 column fied using the primers listed in Table 4 . The primers consist of volumes of 0.1M NiSO, then equilibrated with 10 column a 6 nucleotide buffer followed by a restriction enzyme site 65 volumes of Start Buffer (20 mM NaHPO, 0.5M NaCl, 20 (Sail or XhoI) and sequence specific for Kgp39. PCR was mMimidazole, 8Murea) at a flow rate of 1 ml/min. Samples performed using Taq DNA Polymerase (Promega) under the were loaded onto the columnata flow rate of 0.5 ml/min, then washed with 10 volumes of Start Buffer at a rate of 1 ml/min. Protein was eluted over a linear gradient of 10 volumes of Elution Buffer (20 mM NaHPO, 0.5M NaCl, 200 mMimi dazole, 8Murea) at a flow rate Of 1 ml/min. Elution fractions were collected and samples of each fraction were analysed on SDS-PAGE gels as previously described.
Renaturation of Recombinant Protein
Removal of 8Murea from the recombinant protein samples was achieved using Spectrum-PorR) Float-A-Lyzer (Alltech, Australia). The molarity of urea in the samples was taken from 8M initially to OM over a period of 4 days. rKgp39 proteins were refolded by step-wise dialysis from 8 M to 7 M to 6 Mto 5 MtO4 MtO 3 MtO 2 MtO 1 MtO 0.5M to OMUrea contained in the following buffer: 20 mM NaHPO, 0.5M NaCl Enzyme-LinkedImmunosorbent Assay (ELISA)
ELISAs were performed to investigate the binding of RgpA-Kgp specific antisera to rKgp39 and rKgp39 fragment and the binding ofrkgp39 and rKgp38 fragment to periodon tal matrices and host proteins.
Wells of flat-bottomed polyvinyl microtitre plates (Mi crotitre, Dynatech Laboratories, VA, USA) were coated with 5ug/ml of either rKgp39 or rKgp39 fragment in 0.1M PBS 0.01M NaHPO, 0.15M NaCl, 1.5 mM. KHPO, 3.0 mM KC1, pH 7.4 overnight at room temperature (RT). The coat ing solution was removed and wells were blocked with 1% (w/v) BSA in 0.1M PBST (PBS containing 0.1% (v/v) Tween 20), for 1 hour at RT and plates washed 4x with 0.1M PBST. Serial dilutions of rabbit antisera directed against the P gin givalis W50 Rgp A-Kgp proteinase-adhesin complex (Bhogal et al., 1997) was added to each well and incubated overnight at RT and then washed with 6xPBST. Bound antibody was detected by incubation with horseradish peroxidase-conju gated goat immunoglobulin directed against mouse immuno globulin (1:4000 dilution) (Sigma, NSW, Australia) in 0.5% (w/v) BSA in 0.1M PBS for 1.5 hr at RT. The plates were then washed (6xPBST) and substrate 0.9 mM ABTS (2,2'-azino bis(3-ethylbenz-thiazoline-6-) sulfonic acid, and 0.005% (v/v) HO, in ABTS buffer (0.1M NaHPO, 0.08 M. citric acid monohydrate) (100 ul/well) was added. The optical den sity at 415 nm (ODS) was measured by using a Bio-Rad microplate reader (model 450, BioRad, NSW, Australia). 
Binding of rKgp39 and rKgp39 Fragment to Periodontal
Matrices and Host Proteins
ELISAs were also performed to investigate the binding characteristics of rKgp39 and rKgp39 fragment proteins to the host matrix proteins fibrinogen and collagen type V and to haemoglobin. Microtitre plates were coated with 10 ug/ml of either fibrinogen, collagen type V or haemoglobin in 0.1M PBS overnight at RT. The coating solution was removed and remaining uncoated plastic was blocked with 2% (w/v) Skim milk in 0.1M PBST for 1 hr at RT. The blocking solution was removed and 5ug/ml of either rKgp39 or rKgp39 fragment protein in 0.1M PBS was added to wells and incubated for 2 hrat RT. Wells were washed 4x with 0.1M PBST, then serial dilutions of rabbit anti-Rgp A-Kgp complex anti-sera in 1% (w/v) Skim milk in 0.1M PBST was added to each well and incubated overnight at RT. Bound antibody was detected, after washing 6xPBST, by incubation with horseradish per oxidase conjugated goat immunoglobulin directed against 18 rabbit immunoglobulin (1:4000 dilution) (Sigma, NSW, Aus tralia) in 1% (w/v) Skim milk in 0.1M PBST for 1 hr at RT. The plates were developed as described above.
The results are shown in FIGS. 5 and 6.
EXAMPLE 6
This example illustrates that nucleotide sequences encod ing Rigp A44 or Kgp39 or portions thereof, can be inserted into, and expressed by various vectors including phage vec tors and plasmids. Successful expression of the protein and peptides requires that either the insert comprising the gene or gene fragment, or the vector itself, contain the necessary elements for transcription and translation which is compat ible with, and recognized by the particular host system used for expression. DNA encoding the Rgp A44 or Kgp39 or fragments thereof (e.g. Example 2), or related peptides or oligopeptides or chimeric peptides can be synthesized or isolated and sequenced using the methods and sequences as illustrated herein. A variety of host systems may be utilized to express the RgpA44 or Kgp39 or fragments thereof, related peptides or oligopeptides or chimeras, which include, but are not limited to bacteria transformed with a bacteriophage vec tor, plasmid vector, or cosmid DNA; yeast containing yeast vectors; fungi containing fungal vectors; insect cell lines infected with virus (e.g. baculovirus); and mammalian cell lines transfected with plasmid or viral expression vectors, or infected with recombinant virus (e.g. Vaccinia virus, adenovi rus, adeno-associated virus, retrovirus, etc.).
Using methods known in the art of molecular biology, including methods described above, various promoters and enhancers can be incorporated into the vector or the DNA sequence encoding Rigp A44 or Kgp39 amino acid sequences, i.e., related peptides or oligopeptide or chimeras, to increase the expression of the Rgp A44 or Kgp39 amino acid sequences, provided that the increased expression of the amino acid sequences is compatible with (for example, non toxic to) the particular host cell system used. Thus and impor tantly, the DNA sequence can consist of the genes segment encoding the RgpA44 or Kgp39 or fragments thereof, or any other segment or combined segments of the domain which encode functional and specific epitopes of the protein. Fur ther, the DNA can be fused to DNA encoding other antigens, Such as other bacterial outer membrane proteins, or other bacterial, fungal, parasitic, or viral antigens to create ageneti cally fused (sharing a common peptide backbone) multivalent antigen for use as an improved vaccine composition.
The selection of the promoter will depend on the expres sion system used. Promoters vary in strength, i.e. ability to facilitate transcription. Generally, for the purpose of express ing a cloned gene, it is desirable to use a strong promoter in order to obtain a high level of transcription of the gene and expression into gene product. For example, bacterial, phage, or plasmid promoters known in the art from which a high level of transcription have been observed in a host cell system comprising E. coli include the lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the P and P. pro moters, lacUV5, omple, bla, lpp, and the like, may be used to provide transcription of the inserted DNA sequence encoding amino acid sequences.
Additionally, if protein, related peptides or oligopeptides or chimeras may be lethal or detrimental to the host cells, the host cell Strain/line and expression vectors may be chosen such that the action of the promoter is inhibited until specifi cally induced. For example, in certain operons the addition of specific inducers is necessary for efficient transcription of the inserted DNA (e.g., the lac operon is induced by the addition 19 of lactose or isopropylthio-beta-D-galactoside). A variety of operons such as the trp operon, are under different control mechanisms. The trp operon is induced when tryptophan is absent in the growth media. The P. promoter can be induced by an increase in temperature of host cells containing a tem perature sensitive lambda repressor. In this way, greater than 95% of the promoter-directed transcription may be inhibited in uninduced cells. Thus, expression of recombinant RgpA44 protein, related peptides, or oligopeptides or chimeras may be controlled by culturing transformed or transfected cells under conditions such that the promoter controlling the expression from the inserted DNA encoding Rgp A44 amino acid sequences is not induced, and when the cells reach a Suitable density in the growth medium, the promoter can be induced for expression from the inserted DNA.
Other control elements for efficient gene transcription or message translation include enchancers, and regulatory sig nals. Enhancer sequences are DNA elements that appear to increase transcriptional efficiency in a manner relatively independent of their position and orientation with respect to a nearby gene. Thus, depending on the host cell expression vector System used, an enhancer may be placed either upstream or downstream from the inserted DNA sequences encoding Rigp A44 or Kgp39 amino acid sequences to increase transcriptional efficiency. As illustrated previously in this example, other specific regulatory sequences have been identified which may effect the expression from the gene segment encoding Rigp A44 or Kgp39 and related peptides or chimeras. These or other regulatory sites, such as transcrip tion or translation initiation signals, can be used to regulate the expression of the gene encoding RgpA44 or Kgp39, or gene fragments thereof. Such regulatory elements may be inserted into DNA sequences encoding Rigp A44 or Kgp39 amino acid sequences or nearby vector DNA sequences using recombinant DNA methods described herein for insertion of DNA sequences. Accordingly, P gingivalis nucleotide sequences contain ing regions encoding for Rgp A44 or Kgp39, related peptides, or oligopeptides or chimeras can be ligated into an expression vector at a specific site in relation to the vector's promoter, control, and regulatory elements so that when the recombi nant vector is introduced into the host cell the P gingivalis specific DNA sequences can be expressed in the host cell. For example, the Rgp A44 or Kgp39 specific DNA sequence con taining its own regulatory elements can be ligated into an expression vector in a relation or orientation to the vector promoter and control elements which will allow for expres sion of the RgpA44 or Kgp39 or derivatives. The recombinant vector is then introduced into the appropriate host cells, and the host cells are selected, and screened for those cells con taining the recombinant vector. Selection and screening may be accomplished by methods known in the art including detecting the expression of a marker gene (e.g., drug resis tance marker) present in the plasmid, immunoscreening for production of Rigp A44 or Kgp39 specific epitopes using anti sera generated to Rgp A44 or Kgp39 specific epitopes, and probing the DNA of the hosts cells for Rgp A44 or Kgp39 specific nucleotide sequence using one or more oligonucle otide sequences and methods described herein.
Genetic engineering techniques may also be used to char acterize, modify and/or adapt the encoded RgpA44 or Kgp39 recombinant or protein. For example, site-directed mutagen esis of RgpA44 or Kgp39 or fragments thereof to modify one or all Cys residues to Ser or Ala residues may be desirable to increase the stability and solubility of the recombinant pro tein to allow for easier purification and folding. Further, genetic engineering techniques can be used to generate DNA sequences encoding a portion of the amino acid sequence of RgpA44 or Kgp39 in particular, soluble, hydrophilic sequences corresponding to protective epitopes. Restriction enzyme selection may be done so as not to destroy the immu nopotency of the resultant peptide or oligopeptide orchimera. Antigenic sites of a protein may vary in size but can consist of from about 7 to about 14 amino acids. Thus, RgpA44 or Kgp39 will contain many discrete antigenic sites; therefore, many partial gene sequences could encode antigenic epitopes of Rigp A44 or Kgp39. These sequences can be constructed and used in an expression system to generate highly antigenic chimeric peptides or oligopeptides or proteins. Combinations of two or more peptides may result in increased immunoge nicity. When using combinations of antigens these antigens may be related (i.e. from the same gene sequence or from a closely related gene from the same organism). The antigens may be generated from a related organism (i.e. another oral bacterium present in Subgingival plaque), or from a more distantly-related organism. In particular the host organism for the vector containing the Rgp A44 or Kgp39 related genes and constructs can be a commensal inhabitant of the oral cavity; for example an inhabitant of Subgingival plaque, Supragingi Val plaque or a bacterium associated with the oral mucosa. Examples of commensal intra-oral bacteria would be Strep tococcus species and Actinomyces species, e.g. Streptococcus salivarius, Streptococcus sanguis, Actinomyces naeslundii. These organisms can be isolated from the periodontitis patient and then genetically engineered to express the RgpA44 or Kgp39 or components, peptides or chimeras. The DNA encoding the RgpA44 or Kgp39, peptides or chimeras could be linked with DNA encoding leader sequences of extracellular proteins of these commensal intra-oral bacteria. The DNA encoding the Rgp A44 or Kgp39 or derivatives could also be linked with, or inserted into, the DNA encoding extracellular proteins to produce Secreted fusion proteins. Examples of extracellular proteins that could be used to pro duce fusion proteins with the RgpA44 or Kgp39, compo nents, peptides or chimeras could be the glucosyltranferases (GTF) or fructosyltransferases (FTF). The recombinant organism would be then re-introduced into the patients oral cavity and once colonised the oral mucosa or teeth would express the RgpA44 or Kgp39, component, peptide, chimera or fusion to stimulate the mucosal associated lymphoid tissue to produce neutralising antibodies.
The DNA fragment encoding an antigen may be fused to other DNA sequences to allow for improved expression and/ or purification procedures (i.e. DNA sequences cloned into the vector pTrxFus, are expressed as fusions to the E. coli protein thioredoxin). This linkage imparts the characteristics of thioredoxin to the fusion protein which offers soluble expression of normally insoluble or difficult to express pro teins. After purification, the native protein is released by removal of the entire thioredoxin by digestion with enteroki nase. Furthermore, the antigen may be used as a hapten by fusion to other sequences which may increase immunogenic ity, if the expressed protein or peptide is not immunogenic. Another plasmid expression system involves the puC-de rived pTrchis expression vector from Invitrogen. This vector allows high-level expression of DNA sequences by the pres ence of the Trc promoter (containing the -35 region of the Trp promoter together with the -10 region of the lac promoter) and an irrnB anti-terminator element. The pTrchis vectors also contain a copy of the lac1 gene which encodes the lac repressor protein. Therefore, expression of the recombinant protein/peptide is induced by addition of 1 mM IPTG (de repression) to E. coli grown to mid-log phase. The DNA fragment is inserted into the multiple cloning site which is positioned downstream and in frame with a sequence that encodes an N-terminal fusion peptide. The N-terminal fusion peptide encodes (from 5' to 3'); an ATG translation initiation codon, a series of 6 histidine residues that function as a metal-binding domain in the translated protein, a transcript stabilising the sequence from gene 10 of phage T7, and an enterokinase cleavage recognition sequence. Cell culture lysates of cells harbouring the recombinant plasmid are puri fied by high-affinity binding to ProbondTM resin (Invitrogen). ProbondTM is a nickel-charged sepharose resin that is used to purify recombinant proteins containing a poly-histidine bind ing domain. Bound proteins are eluted from the ProbondTM resin with either low pH buffer or by competition with imi dazole or histidine. The polym-histidine leader peptide may be subsequently removed by digestion of the recombinant expressed protein with Enterokinase. Enterokinase recog nizes the endopeptidase recognition sequence that is engi neered between the poly-his affinity tag and the multiple cloning site in the vector to allow for cleavage of the poly-His tail away from the protein of interest. The purified, recombi nant protein may then be used in the generation of antibodies, vaccines and the formulation of diagnostic assays as dis cussed.
EXAMPLE 7
Methods for using Rgp A44 or Kgp39 specific nucleotide sequences in molecular diagnostic assays for the detection of Pgingivalis. The nucleic acid sequences of the present inven tion can be used in molecular diagnostic assays for detecting P. gingivalis genetic material. In particular, RgpA44 or Kgp39 sequence-specific oligonucleotides can be synthe sized for use as primers and/or probes in amplifying, and detecting amplified, nucleic acids from P gingivalis. Recent advances in molecular biology have provided several means for enzymatically amplifying nucleic acid sequences. Cur rently the most commonly used method, PCRTM (polymerase chain reaction Cetus Corporation) involved the use of Taq Polymerase, known sequences as primers, and heating cycles which separate the replicating deoxyribonucleic acid (DNA) Strands and exponentially amplify a gene of interest. Other amplification methods currently under development include LCRTM (ligase chain reaction, BioTechnica International) which utilizes DNA ligase, and a probe consisting of two halves of a DNA segment that is complementary to the sequence of the DNA to be amplified; enzyme QB replicase (Gene-Trak Systems) and a ribonucleic acid (RNA) sequence template attached to a probe complementary to the DNA to be copied which is used to make a DNA template for exponential production of complementary RNA; and NASBATM (nucleic acid sequence-based amplification, Cangene Corporation) which can be performed on RNA or DNA as the nucleic acid sequence to be amplified.
Nucleic acid probes that are capable of hybridization with specific gene sequences have been used successfully to detect specific pathogens in biological specimens at levels of sensi tivity approaching 10-10' organisms per specimen 1990, Gene Probes for Bacteila, eds. Macario and deMacario, Aca demic Press. Coupled with a method that allows for ampli fication of specific target DNA sequences, species-specific nucleic acid probes can greatly increase the level of sensitiv ity in detecting organisms in a clinical specimen. Use of these probes may allow direct detection without relying on prior culture and/or conventional biochemical identification tech niques. This embodiment of the present invention is directed to primers which amplify species-specific sequences of the gene encoding Rigp A44 or Kgp39 of P gingivalis, and to probes which specifically hybridize with these amplified DNA fragments. By using the nucleic acid sequences of the present invention and according to the methods of the present invention, as few as one P gingivalis organism may be detected in the presence of 10 ug/ml extraneous DNA.
This embodiment is directed to species-specific oligo nucleotides which can be used to amplify sequences of P gingivalis DNA, if present, from DNA extracted from clinical specimens including subgingival plaque, sputum, blood, abscess and other fluids to Subsequently determine if ampli fication has occurred. In one embodiment of the present invention, a pair of P gingivalis-specific DNA oligonucle otide primers are used to hybridize to P gingivalis genomic DNA that may be present in DNA extracted from a clinical specimen, and to amplify the specific segment of genomic DNA between the two flanking primers using enzymatic Syn thesis and temperature cycling. Each pair of primers are designed to hybridize only to the P gingivalis nucleotide sequences of the present invention to which they have been synthesized to complement; one to each strand of the double stranded DNA. Thus, the reaction is specific even in the presence of microgram quantities of heterologous DNA. For the purposes of this description, the primer derived from the sequence of the positive (gene) strand of DNA will be referred to as the "positive primer', and the primer derived from the sequence of the negative (complementary) Strand will be referred to as the "negative primer'. Amplification of DNA may be accomplished by any one of the methods commer cially available. For example, the polymerase chain reaction may be used to amplify the DNA. Once the primers have hybridized to opposite strands of the target DNA, the tem perature is raised to permit replication of the specific segment of DNA across the region between the two primers by a thermostable DNA polyinerase. Then the reaction is ther mocycled so that at each cycle the amount of DNA represent ing the sequences between the two primers is doubled, and specific amplification of the P gingivalis DNA sequences, if present, results. Further identification of the amplified DNA fragment, as being derived from P gingivalis DNA, may be accomplished by liquid hybridization. This test utilizes one or more labeled oligonucleotides as probes to specifically hybridize to the amplified segment of P gingivalis DNA. Detection of the presence of sequence-specific amplified DNA may be accomplished using any one of several methods known in the art such as a gel retardation assay with autora diography. Thus, the nucleotide sequences of the present invention provide basis for the synthesis of oligonucleotides which have commercial applications in diagnostic kits for the detection of P gingivalis. In a related embodiment, the oli gonucleotides used as primers may be labeled directly, or synthesized to incorporate label. Depending on the label used, the amplification products can then be detected, after binding onto an affinity matrix, using isotopic or calorimetric detection.
DNA may be extracted from clinical specimens which may contain P gingivalis using methods known in the art. For example, cells contained in the specimen may be washed in TE buffer and pelleted by centrifugation. The cells then may be resuspended in 100 ul of amplification reaction buffer containing detergents and proteinase K. Using the poly merase chain reaction, the resultant sample may be composed of the cells in 10 mM Tris pH 8.3, 50 mM KC1, 1.5 mM MgCl, 0.01% gelatin, 0.45% NP4OTM, 0.045% Tween 20TM, and 60 ug/ml proteinase K. The sample is incubated in a 55° C. water bath for 1 hour. Following the incubation, the sample is incubated at 95° C. for 10 minutes to heat-inactivate the 23 proteinase K. The sample may then be amplified in accor dance with the protocol for the polymerase chain reaction as set forth below.
The P gingivalis DNA may be amplified using any one of several protocols for amplifying nucleic acids by the poly merase chain reaction. In one mode of this embodiment, the gene encoding the Rgp A44 or Kgp39 may be amplified from clinical isolates of P gingivalis using the following condi tions. DNA to be amplified (1 mg of genomic DNA) is dis tributed to 0.5 ml microfuge tubes and the volume adjusted to 50ulby adding a reaction mixture comprising 0.2 mM dNTPs (dATP, dCTP dOTP, dTTP), 0.25 ug of each positive and negative oligonucleotide primer, 1 unit of Taq polymerase, Taq 10x buffer (5ul), 1 mMMgCl, (final concentration), and sterile distilled water to achieve the total volume. The Taq I polymerase is added to the reaction mixture just before use and is gently mixed, not Vortexed. A layer of mineral oil, approximately 2 drops, is added to each tube and then the tubes are placed in the thermal cycler. Thirty to thirty-five cycles are general sufficient for bacterial DNA amplification. One cycle consists of 1 minute at 95°C., 1 minute at 37°C., and 1 minute at 72°C. The first cycle includes a 1/2 minute incubation at 95°C. to assure complete denaturation.
Oligonucleotides useful as primers or probes which spe cifically hybridize to the gene encoding the Rgp A44 or Kgp39 of Pgingivalis and used in DNA amplification and/or detection can be biochemically synthesized, using methods known in the art, from the nucleotide sequences in the Sequence ID listings herein. For detection purposes, the oli gonucleotides of the present invention may be end-labeled with a radioisotope. Probe sequences, internal to the two primers used for amplification of the gene sequence, may be end-labeled using T4 polynucleotide kinase and gamma 'P ATP. Twenty pMols of probe DNA in kinase buffer (50 mM Tris, pH 7.6 10 mM MgCl, 5 mM dithiothreitol, 0.1 mM spermidine-HCl, 0.1 mM EDTA, pH 8.0) is mixed with 120 uCi of gamma P ATP and incubated at 37° C. for 1 hour.
Labeled probe is separated from unincorporated label on an 8% acrylamide gel run for 1 hour at 200 volts in Tris Borate EDTA (TBE) buffer at room temperature. Labeled probe is first located by exposing the acrylamide gel to X-ray film for three minutes. The resulting autoradiogram is then positioned under the gel, and the band containing the labeled probe was excised from the gel. The gel slice is pulverized in one mil liliter of sterile distilled water, and the probe is eluted by shaker incubation overnight at 37° C. The eluted probe is separated from the gel fragments by centrifugation using a chromatography prep column. Radioactivity of the probe is determined, by counting one microliter of the labeled probe on a glass fibre filter, by liquid scintillation. Such probe sequences may be chosen from any of the sequences dis closed herein provided the probe sequence is internal to the two primers used for amplification of the desired nucleotide sequence disclosed in the present invention.
Alternative methods known in the art may be used to improve the detection of amplified target sequences in accor dance with the compositions and methods of the present invention. The sensitivity of detection of the amplified DNA sequences can be improved by Subjecting the sequences to liquid hybridization. Alternative methods of detection known in the art, in addition to gel electrophoresis and gel electro phoresis with Southern hybridization and autoradiography, that may be used with the compositions and methods of the present invention include: restriction enzyme digestion with gel electrophoresis; slot-blot hybridization with a labeled oligonucleotide probe; amplification with a radiolabeled oli gonucleotide probe; amplification with a radiolabeled primer with gel electrophoresis, Southern hybridization and autora diography; amplification with a radiolabeled primer with dot blot and autoradiography; amplification with oligonucle otides containing affinity tags (ex. biotin, or one primer incor porating biotin and the other primer with a sequence specific for a DNA binding protein) followed by detection in an affin ity-based assay (ex. ELISA); and amplification with oligo nucleotides containing fluorophores followed by fluores cence detection.
One embodiment of non-isotopic detection involves incor porating biotin into the oligonucleotide primers of the present invention. The 5'-amino group of the primers may be bioti nylated with sulfo-NHS-biotin, or biotin may be incorporated directly into the primer by synthesizing the primer in the presence of biotin-labeled dNTPs. The non-isotopic labeled primers are then used in amplifying DNA from a clinical specimen. The detection for the presence or absence of ampli fied target sequences may be accomplished by capturing the amplified target sequences using an affinity matrix having avidin bound thereto, followed by incubation with an avidin conjugate containing an enzyme which can be used to visu alize the complex with Subsequent Substrate development. Alternatively, the amplified target sequences may be immo bilized by hybridization to the corresponding probes of the target sequence wherein the probes have been affixed onto a matrix. Detection may be accomplished using an avidin con jugate containing an enzyme which can be used to visualize the complex with Subsequent Substrate development. EXAMPLE 8 Methods for Using Rgp A44 or Kgp39, Peptides or Chimeric Peptides in Diagnostic Immunoassays.
The RgpA44 or Kgp39 protein, related peptides, oligopep tides or chimeras can be purified for use as immunogens in vaccine formulations; and as antigens for diagnostic assays or for generating P gingivalis-specific antisera of therapeutic and/or diagnostic value. The Rgp A44 or Kgp39 from P gin givalis or oligopeptides or peptides or chimeras thereof, or recombinant protein, recombinant peptides, or recombinant oligopeptides produced from an expression vector system, can be purified with methods known in the art including detergent extraction, chromatography (e.g., ion exchange, affinity, immunoaffinity, or ultrafiltration and sizing col umns), differential centrifugation, differential solubility, or other standard techniques for the purification of proteins.
As used throughout the specification, RgpA44 or Kgp39 oligopeptides are defined herein as a series of peptides cor responding to a portion of the amino acid sequence of the RgpA44 or Kgp39 respectively as disclosed in the enclosed sequences that are synthesized as one or chemically-linked. Such peptides or oligopeptides can be synthesized using one of the several methods of peptide synthesis known in the art including standard Solid phase peptide synthesis using tert butyloxycarbonyl amino acids Mitchell et al., 1978 , J. Org. Chem. 43:2845 -2852 , using 9-fluorenylmethyloxycarbonyl amino acids on a polyamide Support Dryland et al., 1986, J. Chem. So. Perkin Trans. I, 125-137; by pepscan synthesis Leysen et al., 1987, JImmunol Methods 03:259; 1984; and Proc. Natl. Acad. Sci. USA 81:3998 ; by standard liquid phase peptide synthesis; or by recombinant expression vector systems. Modification of the peptides or oligopeptides. Such as by deletion and Substitution of amino acids (and including extensions and additions to amino acids) and in other ways, may be made so as to not substantially detract from the immunological properties of the peptide or oligopeptide. In particular, the amino acid sequences of the Rgp A44 or 25 Kgp39, or peptide or oligopeptide or chimera thereof, may be altered by replacing one or more amino acids with function ally equivalent amino acids resulting in an alteration which is silent in terms of an observed difference in the physicochemi cal behaviour of the protein, peptide, or oligopeptide or chi mera. Functionally equivalent amino acids are known in the art as amino acids which are related and/or have similar polarity or charge. Thus, an amino acid sequence which is Substantially that of the amino acid sequences depicted in the Sequence Listing herein, refers to an amino acid sequence that contains Substitutions with functionally equivalent amino acids without changing the primary biological func tion of protein, peptide, or oligopeptide or chimera.
Purified RgpA44 or Kgp39 protein, peptides, oligopep tides and chimeras may be used as antigens in immunoassays for the detection of P gingivalis-specific antisera present in the body fluid of an individual suspected of having an infec tion caused by P gingivalis. The detection of Rgp A44 or related peptides as an antigen in immunoassays, includes any immunoassay known in the art including, but not limited to, radioinimunoassay, enzyme-linked immunosorbent assay (ELISA), "sandwich' assay, precipitin reaction, agglutina tion assay, fluorescent immunoassay, and chen-liluniines cence-based immunoassay. This embodiment of the present invention is to provide recombinant Rgp A44 or Kgp39 protein and/or peptides or oligopeptides or chimeras thereof, to be used in as immuno gens in a prophylactic and/or therapeutic vaccine for active immunization to protect against or treat infections caused by Pgingivalis. For vaccine purposes, an antigen of Pgingivalis comprising a bacterial protein should be immunogenic, and induce functional antibodies directed to one or more surface exposed epitopes on intact bacteria, wherein the epitope(s) are conserved amongst strains of P gingivalis.
For vaccine development, Rgp A44 or Kgp39 specific amino acid sequences may be purified from a host containing a recombinant vector which expresses Rgp A44 or Kgp39 or related peptides or chimeras. Such hosts include, but are not limited to, bacterial transformants, yeast transformants, fila mentous fungal transformants, and cultured cells that have been either infected or transfected with a vector which encodes RigpA44 or Kgp39 amino acid sequences. The recombinant protein, peptide, or oligopeptide or chimera immunogen is included as the relevant immunogenic material in the vaccine formulation, and in therapeutically effective amounts, to induce an immune response. Many methods are known for the introduction of a vaccine formulation into the human or animal to be vaccinated. These include, but are not limited to, intradermal, intramuscular, intraperitoneal, intra venous, Subcutaneous, ocular, intranasal, and oral adminis tration. The vaccine may further comprise a physiological carrier Such as a solution, a polymer or liposomes; and an adjuvant, or a combination thereof.
Various adjuvants are used in conjunction with vaccine formulations. The adjuvants aid by modulating the immune response and in attaining a more durable and higher level of immunity using Smaller amounts of vaccine antigen or fewer doses than if the vaccine antigen were administered alone. Examples of adjuvants include incomplete Freund's adjuvant (IFA), Adjuvant 65 (containing peanut oil, mannide monooleate and aluminum monostrearate), oil emulsions, Ribi adjuvant, the pluronic polyols, polyamines, Avridine, CRC press, 1992: 49-112 . In addition to the adjuvant the vaccine may include conventional pharma ceutically acceptable carriers, excipients, fillers, buffers or diluents as appropriate. One or more doses of the vaccine containing adjuvant may be administered prophylactically to prevent periodontitis or therapeutically to treat already present periodontitis.
In another preferred composition the preparation is com bined with a mucosal adjuvant and administered via the oral route. Examples of mucosal adjuvants are cholera toxin and heat labile E. coli toxin, the non-toxic B subunits of these toxins, genetic mutants of these toxins which have a reduced toxicity. Other methods which may be utilised to deliver RgpA44 orally include incorporation of the protein into par ticles of biodegradable polymers (such as acrylates or poly esters) by microencapsulation to aid uptake of the micro spheres from the gastrointestinal tract and to protect degradation of the proteins. Liposomes, ISCOMsTM, hydro gels are examples of other potential methods which may be further enhanced by the incorporation of targeting molecules such as LTB, CTB or lectins for delivery of the RgpA44 protein or peptide to the mucosal immune system. In addition to the vaccine and the mucosal adjuvant or delivery system the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers, coatings, dispersion media, antibacterial and antifungal agents, buffers or diluents as appropriate.
Another embodiment of this mode of the invention involves the production of recombinant RgpA44 or Kgp39 specific amino acid sequences as a hapten, i.e. a molecule which cannot by itself elicit an immune response. In Such case, the hapten may be covalently bound to a carrier or other immunogenic molecule which will confer immunogenicity to the coupled hapten when exposed to the immune system. Thus, Such a Rgp A44 or Kgp39 specific hapten linked to a carrier molecule may be the immunogen in a vaccine formu lation.
Another mode of this embodiment provides for either a live recombinant viral vaccine, recombinant bacterial vaccine, recombinant attenuated bacterial vaccine, or an inactivated recombinant viral vaccine which is used to protect against infections caused by P gingivalis. Vaccinia virus is the best known example, in the art, of an infectious virus that is engineered to express vaccine antigens derived from other organisms. The recombinant live vaccinia virus, which is attenuated or otherwise treated so that it does not cause dis ease by itself, is used to immunize the host. Subsequent replication of the recombinant virus within the host provides a continual stimulation of the immune system with the vac cine antigens such as recombinant Rgp A44 or Kgp39 protein, related peptides or chimeras, thereby providing long lasting immunity.
Other live vaccine vectors include: adenovirus, cytomega lovirus, and preferably the poxviruses such as vaccinia Pa oletti and Panicali, U.S. Pat. No. 4,603,112 and attenuated Salmonella strains Stocker et al., U.S. Pat. Nos. 5,210,035, 4,837,151 and 4,735,801; and Curtiss et al., 1988, Vaccine 6:155-160) . Live vaccines are particularly advantageous because they continually stimulate the immune system which can confer Substantially long-lasting immunity. When the immune response is protective against Subsequent P gingi valis infection, the live vaccine itself may be used in a pre ventive vaccine against P gingivalis. In particular, the live vaccine can be based on a bacterium that is a commensal inhabitant of the oral cavity. This bacterium can be trans-5 formed with a vector carrying a recombinant Rgp A44 or Kgp39, peptides, oligopeptides or chimeric peptides and then used to colonise the oral cavity, in particular the oral mucosa. Once colonised the oral mucosa, the expression of the recom binant protein, peptide or chimera will stimulate the mucosal 10 associated lymphoid tissue to produce neutralising antibod ies. To further illustrate this mode of the embodiment, using molecular biological techniques such as those illustrated in Example 8, the genes encoding the RgpA44 or Kgp39 or gene fragments encoding one or more peptides or chimeras may be 15 inserted into the vaccinia virus genomic DNA at a site which allows for expression of epitopes but does not negatively affect the growth or replication of the vaccinia virus vector.
The resultant recombinant virus can be used as the immuno gen in a vaccine formulation. The same methods can be used 20 to construct an inactivated recombinant viral vaccine formu lation except that the recombinant virus is inactivated, such as by chemical means known in the art, prior to use as an immu nogen and without Substantially affecting the immunagenic ity of the expressed immunogen. A mixture of inactivated 25 viruses which express different epitopes may be used in the formulation of a multivalent inactivated vaccine. In either case, the inactivated recombinant vaccine or mixture of inac tivated viruses may be formulated with a suitable adjuvant in order to enhance the immunological response to the vaccine 30 antigens.
In another variation of this embodiment, genetic material is used directly as the vaccine formulation. Nucleic acid (DNA or RNA) containing sequences encoding the Rgp A44 or Kgp39 protein, related peptides or oligopeptides or chimeras, 35 operatively linked to one or more regulatory elements can be introduced directly to vaccinate the individual ("direct gene transfer") against pathogenic strains of P gingivalis. Direct gene transfer into a vaccinated individual, resulting in expres sion of the genetic material by the vaccinated individual's 40 cells such as vascular endothelial cells as well as the tissue of the major organs, has been demonstrated by techniques in the art Such as by injecting intravenously an expression plasmid: cationic liposome complex Zhu et al., 1993, Science 261: 209-211) . Other effective methods for delivering vector DNA 45 into a target cell are known in the art. In one example, purified recombinant plasmid DNA containing viral genes has been used to inoculate (whether parentally, mucosally, or via gene gun immunization) vaccines to induce a protective immune response Fynan et cd. 1993, Proc Natl. Acad Sci USA 50 90:11478-11182. In another example, cells removed from an individual can be transfected or electroporated by standard procedures known in the art, resulting in the introduction of the recombinant vector DNA into the target cell. Cells con taining the recombinant vector DNA may then be selected for 55 using methods known in the art Such as via a selection marker expressed in the vector, and the selected cells may then be re-introduced into the individual to express the Rgp A44 or Kgp39 protein, related peptides or oligopeptides or chimeras.
One preferred method of vaccination with genetic material 60 comprises the step of administering to the individual the nucleic acid molecule that comprises a nucleic acid sequence that encodes the Rgp A44 or Kgp39 protein, related peptides, or oligopeptides or chimeras, wherein the nucleic acid mol ecule is operatively linked to one or more regulatory 65 sequences necessary for expression. The nucleic acid mol ecule can be administered directly, or first introduced into a 28 viral vector and administered via the vector. The nucleic acid molecule can be administered in a pharmaceutically accept able carrier or diluent and may contain compounds that can enhance the effectiveness of the vaccine. These additional compounds include, but are not limited to, adjuvants that enhance the immune response, and compounds that are directed to modulate the immune response, e.g. cytokines, collectively referred to as "immune modulators'; or other compounds which increase the uptake of nucleic acid by the cells, referred to as "nucleic acid uptake enhancers'. The immunization with the nucleic acid molecule can be through any parental route (intravenous, intraperitoneal, intradermal, Subcutaneous, or intramuscular), or via contact with mucosal Surfaces of the nasopharynx, trachea, or gastrointestinal tract.
As an alternative to active immunization, immunization may be passive, i.e. immunization comprising administration of purified immunoglobulin containing antibody against RgpA44 or Kgp39 epitopes. EXAMPLE 10 The following is a proposed example of a toothpaste for mulation containing anti-Rgp A44 or anti-Kgp39 antibodies. balance 32 Throughout this specification the word "comprise', or variations such as "comprises' or "comprising, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the s exclusion of any other element, integer or step, or group of elements, integers or steps. It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive. 
